ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of ImmunityBio, Inc. (NASDAQ:IBRX) have been given an average rating of “Moderate Buy” by the six brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $10.75.

Several research firms recently commented on IBRX. D. Boral Capital restated a “buy” rating and issued a $24.00 price target on shares of ImmunityBio in a research note on Monday, September 8th. Weiss Ratings restated a “sell (d-)” rating on shares of ImmunityBio in a research report on Saturday, September 27th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of ImmunityBio in a research report on Wednesday, September 10th.

ImmunityBio Trading Down 1.2%

ImmunityBio stock opened at $2.50 on Friday. ImmunityBio has a 12 month low of $1.83 and a 12 month high of $7.48. The stock’s 50 day moving average is $2.49 and its 200-day moving average is $2.64. The company has a market capitalization of $2.36 billion, a price-to-earnings ratio of -5.21 and a beta of 0.27.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.10) EPS for the quarter, meeting analysts’ consensus estimates of ($0.10). The firm had revenue of $26.43 million during the quarter, compared to analyst estimates of $21.95 million. As a group, equities research analysts predict that ImmunityBio will post -0.92 earnings per share for the current fiscal year.

Institutional Trading of ImmunityBio

Several large investors have recently modified their holdings of IBRX. Ameriprise Financial Inc. acquired a new stake in shares of ImmunityBio during the 4th quarter worth $38,000. Two Sigma Investments LP acquired a new stake in ImmunityBio during the fourth quarter worth about $72,000. Rhumbline Advisers grew its stake in ImmunityBio by 5.6% during the first quarter. Rhumbline Advisers now owns 219,360 shares of the company’s stock worth $660,000 after buying an additional 11,573 shares in the last quarter. Thrive Wealth Management LLC acquired a new stake in shares of ImmunityBio during the 1st quarter worth approximately $30,000. Finally, Courier Capital LLC boosted its position in shares of ImmunityBio by 33.3% during the 1st quarter. Courier Capital LLC now owns 40,000 shares of the company’s stock worth $120,000 after acquiring an additional 10,000 shares in the last quarter. 8.58% of the stock is owned by institutional investors and hedge funds.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.